Learn why Zack’s has increased its price target on BSEM to $23.25!

Growing revenues have led to another price target increase for BioStem Technologies Inc. (OTC: BSEM) at Zack’s!

Two massive multi-billion-dollar markets for its regenerative therapies position BioStem Technologies Inc. (OTC: BSEM) as a top medtech stock to watch.

The medtech arena is not the easiest to navigate given how many kinds of companies are in it. It’s all about finding emerging players like BSEM who have successfully navigated the regulatory process (a real barrier to entry) and show real growth.

Zack’s Small Cap Research recently increased its price target to $23.25, recognizing the company’s value after it reported Q1 financial results.

Zack’s Small Cap Research has stated, “We reiterate our belief the BSEM is still underpriced even after its recent move higher and continues to represent a good opportunity at recent prices for investors to get in before what we believe will be a more aggressive move higher in the not-too-distant future.”

The company states its mission is “to discover, develop and produce the most effective regenerative medicine products in the world,” and Zack’s believes that the company is well on its way to achieving that goal—providing to investors what the firm believes is an opportunity to invest in a company that is both providing a vital service to the human population and providing economic value to shareholders when doing so.

2023 was a pivotal year for BSEM which has established a solid foundation for the company's future expansion, which now includes a potential uplisting to a senior stock exchange!

See how BioStem Technologies, Inc. (OTC: BSEM) is making waves for its focus on harnessing elements of perinatal tissue derived from the human placenta for manufacturing structural tissue allografts to heal wounds!

This message is a paid advertisement for BioStem Technologies Inc. (OTC: BSEM). The Street Sheet (SS) receives a flat fee totaling up to $3,750. Other than the compensation received for this advertisement sent to subscribers, The Street Sheet and its principals are not affiliated with BioStem Technologies Inc. The Street Sheet and its principals do not own any of the stocks mentioned in this email or in the article that this email links to.

The Street Sheet is a research service not owned or managed by registered brokers and therefore this site does not make any investment recommendations. The information provided in this newsletter is not guaranteed as to the accuracy or completeness. Each user of SS chooses to do trades at their sole discretion and risk. SS is not responsible for gains/losses that may result in the trading of these securities.

This newsletter includes paid advertisements. The source of all third-party content in which SS receives some sort of compensation is clearly and prominently identified herein as "ad", "Sponsored", or “Together With”. Although we have sent you these advertisements, SS does not specifically endorse any third-party product nor is it responsible for the content of the advertisement or the experience with the third-party advertiser. Furthermore, we make no guarantee or warranty about what is advertised.

All investments involve risk, losses may exceed the principal invested, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns.

This communication from The Street Sheet is for informational purposes only. It is not intended to serve as a recommendation to buy, sell, or hold any security and is not an offer or sale of a security. Information contained within should not be perceived as a research report and is not intended to serve as the basis for any investment decision. Any third-party views reflected herein do not reflect the opinion of The Street Sheet. All investments involve risk and the past performance of a security does not guarantee future results or returns. There is always the potential for financial loss when investing in securities or other financial products. The information contained in this newsletter is subject to change without notice, and we do not undertake any obligation to update it. Readers are encouraged to conduct their own research and due diligence and seek advice from licensed professionals regarding their specific financial needs and circumstances. By reading this newsletter, you agree to hold us harmless from any and all losses, liabilities, costs, or expenses arising from your use or reliance on the information provided. The Street Sheet is reader-supported. When you buy through links on our site, we may earn an commission.